0001127602-22-011526.txt : 20220405
0001127602-22-011526.hdr.sgml : 20220405
20220405160815
ACCESSION NUMBER: 0001127602-22-011526
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220404
FILED AS OF DATE: 20220405
DATE AS OF CHANGE: 20220405
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SCHEIBLER LUKAS
CENTRAL INDEX KEY: 0001651281
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38276
FILM NUMBER: 22806840
MAIL ADDRESS:
STREET 1: C/O APELLIS PHARMACEUTICALS, INC.
STREET 2: 6400 WESTWIND WAY, SUITE A
CITY: CRESTWOOD
STATE: KY
ZIP: 40014
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Apellis Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001492422
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 271537290
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 FIFTH AVENUE
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 617-977-5700
MAIL ADDRESS:
STREET 1: 100 FIFTH AVENUE
CITY: WALTHAM
STATE: MA
ZIP: 02451
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2022-04-04
0001492422
Apellis Pharmaceuticals, Inc.
APLS
0001651281
SCHEIBLER LUKAS
C/O APELLIS PHARMACEUTICALS, INC.
100 FIFTH AVENUE, 3RD FLOOR
WALTHAM
MA
02451
1
CHIEF INNOVATION OFFICER
Common Stock
2022-04-04
4
M
0
3504
13.85
A
55737
D
Common Stock
2022-04-04
4
S
0
818
55.84
D
54919
D
Common Stock
2022-04-04
4
S
0
1437
56.864
D
53482
D
Common Stock
2022-04-04
4
S
0
1249
57.805
D
52233
D
Stock Option (Right to Buy)
13.85
2022-04-04
4
M
0
3504
0
D
2029-02-07
Common Stock
3504
50000
D
This is a scheduled exercise and sale from 10B5-1 trading plan.
The sale price range within $1.00. Max. $55.21 - Min. $56.13
The sale price range within $1.00. Max. $56.34 - Min. $57.22
The sale price range within $1.00. Max. $57.37 - Min. $58.29.
This represents a stock option grant made on 02/08/2019 that vests as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to the satisfaction of a specified performance condition and continued service.
/s/ David Watson, attorney-in-fact for Lukas Scheibler
2022-04-05